IFL:ASXInsignia Financial Ltd Analysis
Data as of 2026-05-18 - not real-time
A$4.80
Latest Price
4/10Risk
Risk Level: Medium
Executive Summary
Insignia Financial (IFL) is trading near its recent support of $4.75 and resistance of $4.80, with the 20‑day SMA ($4.78) sitting just above the 50‑day SMA ($4.72) and the 200‑day SMA ($4.58), indicating a short‑term bullish alignment. The RSI of 68.5 suggests momentum is strong but not yet overbought, while the MACD histogram is slightly negative, hinting at a potential near‑term pull‑back. Fundamentally, the company posts a 7.8% revenue growth year‑over‑year and a healthy gross margin of 47%, yet its trailing PE of 28.2 is well above the industry average of 16.7, signaling current overvaluation; the forward PE of 11.7 narrows this gap as earnings are expected to accelerate. Debt remains sizable at a debt‑to‑equity of 47.9% and free cash flow is negative, which tempers the optimism from operating margins of 21% and a ROE of only 5.4%.
The decisive catalyst is the court‑approved takeover by Daintree BidCo offering $4.80 cash per share, effectively locking in the current price and ending public trading as of April 28 2026. With the market sentiment reflected in an “Extreme Greed” reading (89.6) and a low beta (~0.19), upside potential is limited, but the cash‑out deal removes execution risk and provides a clear, albeit modest, return to shareholders.
The decisive catalyst is the court‑approved takeover by Daintree BidCo offering $4.80 cash per share, effectively locking in the current price and ending public trading as of April 28 2026. With the market sentiment reflected in an “Extreme Greed” reading (89.6) and a low beta (~0.19), upside potential is limited, but the cash‑out deal removes execution risk and provides a clear, albeit modest, return to shareholders.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Takeover cash offer of $4.80 per share
- Technical support at $4.75 and resistance at $4.80
- Limited upside due to deal completion
Medium Term
1–3 yearsNeutral
Model confidence: 7/10
Key Factors
- Deal certainty after court approval
- Cash distribution eliminates valuation upside
- Negative free cash flow and moderate debt profile
Long Term
> 3 yearsCautious
Model confidence: 8/10
Key Factors
- Company will be taken private and delisted
- No dividend and low ROE limit long‑term returns
- Post‑deal lack of tradable equity eliminates holding value
Key Metrics & Analysis
Financial Health
Revenue Growth7.80%
Profit Margin6.80%
P/E Ratio28.2
ROE5.36%
ROA6.03%
Debt/Equity47.87
P/B Ratio1.5
Op. Cash FlowA$286.2M
Free Cash FlowA$-52987500
Industry P/E16.7
Technical Analysis
TrendBullish
RSI68.5
SupportA$4.75
ResistanceA$4.80
MA 20A$4.78
MA 50A$4.72
MA 200A$4.58
MACDBearish
VolumeDecreasing
Fear & Greed Index89.61
Valuation
Target PriceA$4.80
GradeFair
TypeBlend
Risk Assessment
Beta0.19
Volatility4.55%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.